88 related articles for article (PubMed ID: 9617511)
21. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.
Lu PH; Masterman DA; Mulnard R; Cotman C; Miller B; Yaffe K; Reback E; Porter V; Swerdloff R; Cummings JL
Arch Neurol; 2006 Feb; 63(2):177-85. PubMed ID: 16344336
[TBL] [Abstract][Full Text] [Related]
22. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
23. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
24. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
25. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Jenike MA; Albert MS; Heller H; Gunther J; Goff D
J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
[TBL] [Abstract][Full Text] [Related]
27. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT
Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605
[TBL] [Abstract][Full Text] [Related]
28. Lack of efficacy of hydergine in patients with Alzheimer's disease.
Thompson TL; Filley CM; Mitchell WD; Culig KM; LoVerde M; Byyny RL
N Engl J Med; 1990 Aug; 323(7):445-8. PubMed ID: 2082953
[TBL] [Abstract][Full Text] [Related]
29. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease.
Heyman A; Schmechel D; Wilkinson W; Rogers H; Krishnan R; Holloway D; Schultz K; Gwyther L; Peoples R; Utley C
J Neural Transm Suppl; 1987; 24():279-86. PubMed ID: 3479525
[TBL] [Abstract][Full Text] [Related]
30. The use of selegiline in Alzheimer's patients with behavior problems.
Goad DL; Davis CM; Liem P; Fuselier CC; McCormack JR; Olsen KM
J Clin Psychiatry; 1991 Aug; 52(8):342-5. PubMed ID: 1907964
[TBL] [Abstract][Full Text] [Related]
31. Effects of phosphatidylserine in Alzheimer's disease.
Crook T; Petrie W; Wells C; Massari DC
Psychopharmacol Bull; 1992; 28(1):61-6. PubMed ID: 1609044
[TBL] [Abstract][Full Text] [Related]
32. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
Sevush S; Guterman A; Villalon AV
J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
[TBL] [Abstract][Full Text] [Related]
33. Behavioral effects of trazodone in Alzheimer's disease.
Lebert F; Pasquier F; Petit H
J Clin Psychiatry; 1994 Dec; 55(12):536-8. PubMed ID: 7814348
[TBL] [Abstract][Full Text] [Related]
34. Low dose oral haloperidol and blood levels in Alzheimer's disease: a preliminary study.
Devanand DP; Cooper T; Sackeim HA; Taurke E; Mayeux R
Psychopharmacol Bull; 1992; 28(2):169-73. PubMed ID: 1513920
[TBL] [Abstract][Full Text] [Related]
35. Noradrenergic intervention in Alzheimer's disease.
Crook T; Wilner E; Rothwell A; Winterling D; McEntee W
Psychopharmacol Bull; 1992; 28(1):67-70. PubMed ID: 1609045
[TBL] [Abstract][Full Text] [Related]
36. Behavioral effects of a synthetic corticotropin 4-9 analog in patients with depression and patients with Alzheimer's disease.
Heuser I; Heuser-Link M; Gotthardt U; Grasser A; Holsboer F
J Clin Psychopharmacol; 1993 Jun; 13(3):171-4. PubMed ID: 8394847
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.
Asthana S; Greig NH; Holloway HW; Raffaele KC; Berardi A; Schapiro MB; Rapoport SI; Soncrant TT
Clin Pharmacol Ther; 1996 Sep; 60(3):276-82. PubMed ID: 8841150
[TBL] [Abstract][Full Text] [Related]
38. Transcranial direct current stimulation as a memory enhancer in patients with Alzheimer's disease: a randomized, placebo-controlled trial.
Bystad M; Grønli O; Rasmussen ID; Gundersen N; Nordvang L; Wang-Iversen H; Aslaksen PM
Alzheimers Res Ther; 2016 Mar; 8(1):13. PubMed ID: 27005937
[TBL] [Abstract][Full Text] [Related]
39. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
McLachlan DR; Smith WL; Kruck TP
Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
[TBL] [Abstract][Full Text] [Related]
40. Controlled study on the cognitive and psychological effect of coloring and drawing in mild Alzheimer's disease patients.
Hattori H; Hattori C; Hokao C; Mizushima K; Mase T
Geriatr Gerontol Int; 2011 Oct; 11(4):431-7. PubMed ID: 21518170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
